{{Rsnum
|rsid=928655
|Gene=GBP6
|Chromosome=1
|position=89384015
|Orientation=plus
|GMAF=0.4408
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=GBP6
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 52.2 | 41.6 | 6.2
| HCB | 13.1 | 46.0 | 40.9
| JPT | 8.0 | 52.2 | 39.8
| YRI | 12.2 | 58.5 | 29.3
| ASW | 28.1 | 47.4 | 24.6
| CHB | 13.1 | 46.0 | 40.9
| CHD | 9.2 | 58.7 | 32.1
| GIH | 44.6 | 42.6 | 12.9
| LWK | 29.1 | 49.1 | 21.8
| MEX | 37.9 | 50.0 | 12.1
| MKK | 34.0 | 47.4 | 18.6
| TSI | 55.9 | 36.3 | 7.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs928655
|Name_s=
|Gene_s=GBP6
|Feature=
|Evidence=PubMed ID:18615156
|Annotation=This variant is significantly associated with the efficacy of anti-TNF treatment in rheumatoid arthritis (Adjusted P-value: 0.00003; OR: 5.5 (1.8, 20.2)). The study is a genome-wide association study using the Illumina HapMap300 SNP chip on 89 RA patients prospectively followed after beginning of anti-TNF therapy.
|Drugs=adalimumab; etanercept; infliximab
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA162928819
}}

{{PMID|20423481|OA=1
}} Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs928655
|overall_frequency_n=73
|overall_frequency_d=128
|overall_frequency=0.570312
|n_genomes=41
|n_genomes_annotated=0
|n_haplomes=57
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}